Emanuele Andreano

Head Serology and Immunology | Fondazione Biotecnopolo di Siena | Immunology | Monoclonal Antibodies | Vaccinology | Infectious Diseases 🇮🇹

[Emanuele Andreano @e_andreano]

I am delighted to share our last work on the in vitro evolution of a SARS-CoV-2 variant able to escape from a COVID-19 neutralizing plasma. @FondazioneTLS @VisMederi @AreaSciencePark @RommieAmaro Lab @McLellan_Lab

https://t.co/Rd8FwFJqeG

[CVIMP @WashU_CVIMP]

As part of our 2025 “Rising Stars in #Vaccinology and #Immunity to #Microbes” seminar series, we spoke with Dr. Emanuele Andreano @e_andreano who uses #immunology, #structural_biology and #artificial_intelligence to develop antiviral countermeasures. https://t.co/38TjYcpYoH

[Emanuele Andreano @e_andreano]

Our new work on monoclonal antibodies to fight #gonorrhea just got out on @ScienceTM!
We are unleashing the full power of antibodies to accelerate vaccine development and new solutions to #AMR

Check the full paper out 👇
https://t.co/mKCkZAOBM2

[Science Translational Medicine @ScienceTM]

Why do #mengingococcus vaccines partially protect against #gonorrhea?

Researchers identify antigens responsible for cross-protection and identify cross-reactive antibodies that can shield mice from gonococcus infection. @e_andreano @FondazioneTLS https://t.co/sbsQlS3W3n

[Emanuele Andreano @e_andreano]

@CellReports Great to see our work published on @CellReports

[Cell Reports @CellReports]

Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses https://t.co/RKaNrUC17W

[Emanuele Andreano @e_andreano]

Big thanks to the whole #MADLab at @FondazioneTLS and our incredible collaborators for the amazing effort @Virus_Immunity @NJTemperton #PietMaes #EtienneSimonLoriere @institutpasteur #UniversityofKent @unisiena #KULeuven

[Emanuele Andreano @e_andreano]

Over the last 4 years our immune system kept evolving to fight SARS-CoV-2. In our last work, published on @CellReports, we longitudinally analyzed different cohorts to understand the evolution of the antibody response to SARS-CoV-2.
Here the full paper: https://t.co/CKzvTMw6dH

[Olivier Schwartz Lab @Virus_Immunity]

Antigenic sin and multiple breakthrough infections drive converging evolution
of COVID-19 neutralizing responses
https://t.co/H7IlpOg5lO

[Emanuele Andreano @e_andreano]

We interrogated our panel of almost 900 neutralizing human monoclonal antibodies to understand how JN.1 was able to evade the antibody response and become the main SARS-CoV-2 variant worldwide.
Check the full paper out published in Science Immunology: https://t.co/o1pxsaCRn8

[Waggoner Lab @LabWaggoner]

SARS-CoV-2 JN.1 variant L455S sequence abolishes the neutralizing antibody response of the publicly shared IGHV3-53/3-66, contributing to its global spread @SciImmunology @e_andreano Rappuoli
https://t.co/oAs6eKESw9

[bioRxiv Immunology @biorxiv_immuno]

B cell maturation restored ancestral germlines to control Omicron BA.2.86 https://t.co/mZQJKxXtWF #biorxiv_immuno

[Emanuele Andreano @e_andreano]

@KonLontos In addition, it also depends from the individual pre-exposure to the virus. If you already had Omicron infection, the heterogenous exposure to SARS-CoV-2 S proteins (Wuhan + omicron) imporves the response

[Emanuele Andreano @e_andreano]

How the unceasing interplay between B cell response and SARS-CoV-2 pushed their continuous evolution? To answer this question we interrogated a panel of almost 1,000 neutralizing human monoclonal antibodies built over the last three years. Check it out: https://t.co/kWnDjm2l3t

[Emanuele Andreano @e_andreano]

@KonLontos It seems that this is due to the presence of pre-expanded and hypermutated B cell germlines ready to be restored and that, after additional maturation, can be re-employed to control the new variant.

[Emanuele Andreano @e_andreano]

A big thanks goes to all the people involved in this study #MADlab @FondazioneTLS @unisiena #UniversityofKent @KULeuven @institutpasteur @NJTemperton @Virus_Immunity

[Professor Nigel Temperton 👨‍🎓🎧🇪🇺 @NJTemperton]

B cell maturation restored ancestral germlines to control Omicron BA.2.86 | bioRxiv fantastic collaboration with Monoclonal Antibody Discovery (MAD) lab, ⁦@FondazioneTLS⁩ Siena, Italy 🇮🇹 https://t.co/nqPCqH0e45

[Rommie Amaro @RommieAmaro]

... and this 'impossible review' on the future of cell & molecular biology marks the Amaro Lab's 200th paper

🍾🤓💜

So grateful & proud of this wonderful group, all members, past & present, helping make these impossible (nerd) dreams come true! 🥰❤️

[Rommie Amaro @RommieAmaro]

We are standing on the cusp of a new era of biology, where the integration of multimodal structural datasets with multiscale physics-based simulation will enable the development of visible, virtual cells.

My dream for #COVIDisAirborne @kprather88 & the molecular basis of life 😍❤️🤓

https://t.co/2SMJLcQlBL

[Olivier Schwartz Lab @Virus_Immunity]

Another example of #SARSCoV2 infected cells forming syncytia.
Label-free holotomography and AI-based image analysis
#Nanolive microscope

https://t.co/h2lDiimr4z

[Emanuele Andreano @e_andreano]

#AMR is a silent pandemic and new tools are needed to treat and prevent bacterial infection.
In our latest work, we have identified human monoclonal antibodies able to kill Gonococcus, a bacterium resistant to almost all class of antibiotics.
Check it out: https://t.co/PEvDxcu2eF

[bioRxiv Immunology @biorxiv_immuno]

Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens https://t.co/c7e75AEeS2 #biorxiv_immuno